These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28668172)

  • 1. Update concept of the dual blocking of the renin-angiotensin-aldosteron system. A new therapeutic option?
    León Jiménez D; Castilla Guerra L; López Chozas JM; Miramontes González JP
    Med Clin (Barc); 2018 Jan; 150(1):33-38. PubMed ID: 28668172
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the renin angiotensin system for remission/regression of chronic kidney disease.
    Macconi D
    Histol Histopathol; 2010 May; 25(5):655-68. PubMed ID: 20238303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming the Care of Patients with Diabetic Kidney Disease.
    Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE;
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual renin-angiotensin system blockade for nephroprotection.
    Ruggenenti P
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual renin-angiotensin-aldosterone system inhibition: boon or bust?
    Hirsch S
    Int J Clin Pract; 2010 Sep; 64(10):1337-40. PubMed ID: 20716140
    [No Abstract]   [Full Text] [Related]  

  • 7. Limitations of angiotensin inhibition.
    Nobakht N; Kamgar M; Rastogi A; Schrier RW
    Nat Rev Nephrol; 2011 Jun; 7(6):356-9. PubMed ID: 21502972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential RAAS blockade: is it worth the risk?
    Persson F; Rossing P
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):159-65. PubMed ID: 24602465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slowing Progression in CKD: DAPA CKD and Beyond.
    Larmour K; Levin A
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1117-1119. PubMed ID: 33692116
    [No Abstract]   [Full Text] [Related]  

  • 10. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
    Dalla Vestra M; Simioni N; Masiero A
    Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Kidney disease and RAS].
    Kimura G
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1756-61. PubMed ID: 17037311
    [No Abstract]   [Full Text] [Related]  

  • 12. Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.
    Gentile G; Remuzzi G; Ruggenenti P
    Nephron; 2015; 129(1):39-41. PubMed ID: 25531311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH; Luft FC
    Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK; Epstein M
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract]   [Full Text] [Related]  

  • 15. Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
    Rossing P; Parving HH; de Zeeuw D
    Nephrol Dial Transplant; 2006 Sep; 21(9):2354-7; discussion 2357-8. PubMed ID: 16928724
    [No Abstract]   [Full Text] [Related]  

  • 16. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renin-angiotensin system].
    Ito S
    Nihon Jinzo Gakkai Shi; 2007; Suppl 50th Ann():103-6. PubMed ID: 17899835
    [No Abstract]   [Full Text] [Related]  

  • 19. [RAS blockade in diabetic nephropathy. "Early intervention can dramatically decrease loss of function].
    Ritz E
    MMW Fortschr Med; 2004 Sep; 146(38):12. PubMed ID: 15532423
    [No Abstract]   [Full Text] [Related]  

  • 20. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.